c-Met signaling raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-01-16. Anything still debated is marked as such rather than presented as settled.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
| Property | Value | Notes |
|---|---|---|
| Chemical name | N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Common full name in research literature. |
| Class | Synthetic peptide | Modified angiotensin IV analog. |
| Related compound | Angiotensin IV | Parent peptide fragment. |
| Proposed target | HGF/c-Met pathway | Described as an HGF mimetic; not fully confirmed. |
| Development status | Preclinical research | No widely approved clinical use. |
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
Purity and identity are usually assessed with reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry. RP-HPLC separates components by hydrophobicity and can estimate peptide purity. Mass spectrometry confirms molecular mass and helps detect truncations or modifications. Some laboratories also use amino acid analysis or nuclear magnetic resonance for structural verification. A certificate of analysis from a supplier may list these results, but independent verification is often recommended for critical work.
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
=== Project PREPARE === The European PREPARE project aims to fill gaps in nuclear and radiological emergency preparedness identified after the Fukushima accident. The project aims to review emergency response concepts for long-lived releases, to address issues of measurement methods and food safety in the case of transboundary contamination, and to fill gaps in decision support systems (source term reconstruction, improved dispersion modeling, consideration of aquatic dispersion pathways in European river systems).
High Voltage Engineering Corporation accelerators originated with the electrostatic generator designed by MIT physicist Robert J. Van de Graaff. In an effort to split the atom, Van de Graaff devised a electrostatic method to accelerate and direct charged particles at high voltages. While constructing a high-voltage prototype accelerator in the early 1930s, Van de Graaff patented several technologies that would form part of the future company's technology base. MIT professor John G. Trump, an apprentice of Van de Graaff, focused on making the generators useful for cancer radiotherapy. In the 1930s, few hospitals could afford radium sources, available x-ray sources were insufficiently powerful, and both methods damaged healthy tissues. Trump proposed that the unlimited, controllable beam output of Van de Graaff devices could make treatment affordable and safer. He built a series of compact "supervoltage" (>1-megavolt) x-ray generators for local cancer hospitals and secured further patents for the smaller generators. Returning from his World War II leave, Trump received requests from several British hospitals for new cancer generators and decided a company could better fulfill further orders. He recruited Van de Graaff to serve as co-founder and chief scientist. Neither professor wished to leave MIT, so Trump brought in British physicist Denis M. Robinson as a third co-founder and president. In 1946, Trump approached his wartime colleague, MIT President Karl Compton, about supporting the venture.
== Further reading == Maliene, V.; Deveikis, S.; Kirsten, L.; Malys, N. (2010). "Commercial Leisure Property Valuation: A Comparison of the Case Studies in UK and Lithuania". International Journal of Strategic Property Management. 14 (1): 35–48. doi:10.3846/ijspm.2010.04.
Pure culture yeasts that are grown in a lab are often freeze dried and packaged for commercial use. Prior to their addition into must, these yeasts need to be re-hydrated in "starter cultures" that must be carefully monitored (particularly in regards to temperature) to ensure that the yeast cells are not killed off by cold shock. Ideally winemakers want to add enough inoculum to have a viable cell population density of 5 million cells per milliliter. The exact amount of freeze-dried culture varies by manufacturer and strain of yeast but it is often around 1 gram per gallon (or 25 grams per 100 liters). Wines that could have potentially problematic fermentation (such as high sugar level late harvest or botryized wines) may have more yeast added. Similarly, re-hydration procedures will also vary depending on the manufacturer and winery. Yeast is often inoculated in a volume of water or grape must that is 5–10 times the weight of the dry yeast. This liquid is often brought to temperature of 40 °C (104 °F) prior to the introduction of the yeast (though some yeast strains may need temperatures below 38 °C (100 °F)) to allow the cells to disperse easily rather than clump and sink to the bottom of the container. The heat activation also allows the cells to quickly reestablish their membrane barrier before soluble cytoplasmic components escape the cell. Re-hydration at lower temperatures can greatly reduce the viability of the yeast with up to 60% cell death if the yeast is re-hydrated at 15 °C (59 °F).
Sources: en.wikipedia.org
==== Myasthenia gravis ==== Myasthenia gravis is an autoimmune disease most often caused by antibodies that block acetylcholine receptors, which are responsible for signaling between nerves and muscles. It is often associated with thymic hyperplasia or thymoma, with antibodies produced probably because of abnormally developed T cells. Myasthenia gravis most often develops between young and middle age, causing easy fatiguing of muscle movements. Investigations include demonstrating antibodies (such as against acetylcholine receptors or muscle-specific kinase), and CT scan to detect thymoma or thymectomy. Concerning the thymus, removal of the thymus, called thymectomy, may be considered as a treatment, particularly if a thymoma is found. Other treatments include increasing the duration of acetylcholine action at nerve synapses by decreasing the rate of breakdown. This is done by acetylcholinesterase inhibitors such as pyridostigmine.
== Safety == The safety of research chemicals is untested and little if any research has been done on the toxicology or pharmacology of most of these drugs. Few, if any, human or animal studies have been done. Many research compounds have produced unexpected side-effects and adverse incidents due to the lack of screening for off-target effects prior to marketing; both Bromo-DragonFLY and mephedrone seem to be capable of producing pronounced vasoconstriction under some circumstances, which has resulted in several deaths, although the mechanism remains unclear. Substituted phenethylamines such as the 2C family and substituted amphetamines such as the DOx family have also caused a limited number of deaths.
=== Primary or secondary === The distinction between primary and secondary immunodeficiencies is based on whether the cause originates in the immune system itself or insufficiency of a supporting component or an external factor.
=== Treatment === The US CDC reports no specific antidote for azide poisoning. A 2021 narrative review identifies several cases of survival from ingestion when the patient is treated with antidotes for cyanide poisoning. From a mechanistic standpoint, hydroxocobalamin is more likely to be helpful than other antidotes such as sodium nitrite and sodium thiosulfate. As a result, the recommended treatment is hemodynamic support and hydroxocobalamin. First responders should use personal protection equipment to protect themselves from azide exposure.
Relatedly, psilocybin has been found not to enhance but rather to inhibit hippocampal neurogenesis in rodents. Psilocybin acutely increases cortisol levels and has been found to activate many glucocorticoid-responsive genes in animals, which may be due to an acute stress response and could be involved in its longer-lasting effects. Psilocybin produces profound anti-inflammatory effects mediated by serotonin 5-HT2A receptor activation in preclinical studies. These effects have a potency similar to that of (R)-DOI, and its anti-inflammatory effects occur at far lower doses than those that produce hallucinogen-like effects in animals. Psilocybin's anti-inflammatory effects might be involved in its potential antidepressant benefits and might also have other therapeutic applications, such as treatment of asthma and neuroinflammation. They may also be involved in microdosing effects. But psychedelics have been found to have anti-inflammatory effects only in the setting of preexisting inflammation and may be pro-inflammatory outside that context. Psilocybin has been found to have a large, long-lasting effect on the gut microbiome and to influence the gut–brain axis in animals. These effects are partially but not fully dependent on its activation of the serotonin 5-HT2A and/or 5-HT2C receptors. Some of psilocybin's behavioral and potential therapeutic effects may be mediated by changes to the gut microbiome. Transplantation of intestinal contents of psilocybin-treated rodents to untreated rodents resulted in behavioral changes consistent with those of psilocybin administration.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.
No, dihexa is a synthetic compound derived from the structure of angiotensin IV. Angiotensin IV occurs naturally, but dihexa has modifications that change its properties. It is not a standard dietary component.
The main hypothesis is that dihexa interacts with the hepatocyte growth factor system, possibly through c-Met signaling. This interaction may influence synaptogenesis and neuronal plasticity. The exact molecular target remains an active area of study.
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.